- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07481734
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (TESA-LIVER)
Un Estudio Aleatorizado, Doble Ciego, Controlado con Placebo de Fase II de Tesamorelina (Análogo de GHRH) para Reducir la Esteatosis Hepática en Adultos con Enfermedad del Hígado Graso Asociada a Metabolismo (MASLD)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Fatty liver disease (MASLD/NAFLD) is common and may progress to steatohepatitis and fibrosis. There are limited pharmacologic options that directly and durably reduce hepatic steatosis while also improving metabolic risk. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that increases endogenous pulsatile growth hormone secretion and can influence lipid metabolism. Prior randomized studies of tesamorelin have shown reductions in hepatic fat fraction in populations with NAFLD, using magnetic-resonance-based quantification and paired histology in subsets. The primary efficacy endpoint is change in liver fat (MRI-PDFF) from baseline to week 52. Secondary endpoints include MRI-PDFF responder rate (>=30% relative decline), changes in liver enzymes and noninvasive fibrosis measures, metabolic outcomes (glucose, HbA1c, HOMA-IR, lipids), and safety/tolerability outcomes. In this protocol, eligible adults with elevated liver fat on MRI-PDFF are randomized 1:1 to tesamorelin or placebo. Study medication is self-administered once daily by subcutaneous injection.
Dose reduction rules are included for elevated IGF-1 while preserving the blind.
Participants complete study visits at baseline and at weeks 4, 12, 24, 36, and 52 (end of treatment), plus a safety follow-up at week 56. MRI-PDFF is performed at baseline, week 24, and week 52. Transient elastography (FibroScan) and standard laboratory panels are collected at prespecified visits. A voluntary liver-biopsy sub-study is offered to evaluate histologic activity and fibrosis.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Seni S Lu, Phd
- Número de teléfono: +86 13076790030
- Correo electrónico: Seni-Lu@beijing-biotech.com
Ubicaciones de estudio
-
-
Guangdong
-
Shenzhen, Guangdong, Porcelana, 518036
- Reclutamiento
- Peking University Shenzhen Hospital
-
Contacto:
- Zhen J Peng, Phd
- Número de teléfono: +86 13076790039
- Correo electrónico: Zhen-Peng@beijing-biotech.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults age 18 to 75 years, able to provide informed consent.
- Evidence of hepatic steatosis consistent with MASLD/NAFLD, defined as MRI-PDFF >=10% at screening (or equivalent imaging documentation if MRI-PDFF was performed within the prior 8 weeks).
- Fibrosis risk compatible with non-cirrhotic disease (e.g., FibroScan liver stiffness below a prespecified threshold and no clinical evidence of portal hypertension).
- Stable body weight (+/-5%) for at least 3 months prior to screening.
- If on diabetes, lipid-lowering, antihypertensive, or weight-loss medications, regimen is stable for at least 3 months prior to screening and expected to remain stable through week 52.
- Willingness and ability to self-administer daily subcutaneous injections (or have a trained caregiver).
- For participants of childbearing potential: agreement to use reliable contraception during treatment and for 30 days after the last dose; negative pregnancy test at screening and baseline.
Exclusion Criteria:
- Significant alcohol consumption consistent with alcohol-associated liver disease (e.g., >20 g/day for women or >30 g/day for men for sustained periods).
- Other chronic liver diseases (e.g., chronic hepatitis B, chronic hepatitis C with viremia, autoimmune hepatitis, Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency).
- Known cirrhosis or decompensated liver disease; or biopsy-proven stage 4 fibrosis if baseline biopsy is performed.
- Poorly controlled diabetes or conditions increasing ocular risk (e.g., HbA1c at or above a protocol threshold; active/untreated diabetic retinopathy).
- Use of exogenous growth hormone or GHRH analogs within the past 12 months.
- Chronic systemic corticosteroids or chronic use of medications known to induce or worsen steatosis or liver injury (e.g., amiodarone, tamoxifen, methotrexate).
- Active malignancy or high risk for recurrence judged unsafe by investigators.
- Contraindications to MRI (e.g., certain implanted devices) if MRI-PDFF is required.
- Pregnancy or breastfeeding.
- Known hypersensitivity to tesamorelin or formulation excipients (e.g., mannitol).
- Bariatric surgery within the last 12 months, or planned bariatric surgery during the study period.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Experimental: Tesamorelina 2 mg por vía subcutánea una vez al día (con algoritmo de reducción de dosis para I elevada
|
for injection, 2 mg SC once daily; participant self-administration after training. Dose may be reduced to 1 mg daily if IGF-1 z-score meets protocol threshold. for injection (mannitol-based, identical appearance), SC once daily. dietary guidance and physical activity recommendations,delivered at baseline and reinforced at each visit. |
|
Experimental: Placebo comparador: Placebo coincidente subcutáneo una vez al día
|
for injection, 2 mg SC once daily; participant self-administration after training. Dose may be reduced to 1 mg daily if IGF-1 z-score meets protocol threshold. for injection (mannitol-based, identical appearance), SC once daily. dietary guidance and physical activity recommendations,delivered at baseline and reinforced at each visit. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points)
Periodo de tiempo: 52 weeks
|
MRI-PDFF performed at baseline and week 52; central blinded read. |
52 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cambio en la glucosa en ayunas
Periodo de tiempo: 52 semanas
|
52 semanas
|
|
|
Cambio en lípidos en ayunas
Periodo de tiempo: 52 semanas
|
52 semanas
|
|
|
Cambio en el volumen del tejido adiposo visceral (TAV)
Periodo de tiempo: 52 semanas
|
52 semanas
|
|
|
MRI-PDFF responder rate (>=30% relative decline from baseline)
Periodo de tiempo: 52 weeks
|
Responder analysis using MRI-PDFF values (baseline vs week 52). |
52 weeks
|
|
Change in ALT
Periodo de tiempo: 52 weeks
|
Clinical chemistry panel at baseline and scheduled visits. |
52 weeks
|
|
Change in liver stiffness by transient elastography
Periodo de tiempo: 52 weeks
|
FibroScan liver stiffness measurement; performed per site SOP. |
52 weeks
|
|
Change in controlled attenuation parameter (CAP) by transient elastography
Periodo de tiempo: 52 weeks
|
FibroScan CAP measurement |
52 weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TESA-MASLD-201
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .